Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931202 | 0.88 | BACE1 (0.59) | BACE1KCNH2BACE2 | |
| SCHEMBL931151 | 0.87 | BACE1 (0.51) | BACE1KCNH2BACE2MEN1NPC1 | |
| SCHEMBL932477 | 0.85 | BACE1 (0.52) | BACE1KCNH2BACE2MEN1NPC1 | |
| SCHEMBL1025970 | 0.80 | BACE1 (0.53) | BACE1KCNH2BACE2MEN1NPC1 | |
| SCHEMBL6891921 | 0.75 | BACE1 (0.52) | BACE1 | |
| SCHEMBL10156423 | 0.74 | BACE1 (0.79) | BACE1 | |
| SCHEMBL932487 | 0.72 | BACE1 (0.60) | BACE1BACE2 | |
| SCHEMBL296988 | 0.72 | BACE1 (0.80) | BACE1 | |
| SCHEMBL932230 | 0.69 | BACE1 (0.59) | BACE1KCNH2BACE2 | |
| SCHEMBL18926487 | 0.69 | BACE1 (0.65) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |